Researchers at McMaster University have invented a stable, affordable way to store fragile vaccines for weeks at a time at temperatures up to 40C, opening the way for life-saving anti-viral vaccines to reach remote and impoverished regions of the world.
The new method combines the active ingredients in existing vaccines with a sugary gel, where they remain viable for eight weeks or more, even at elevated temperatures.
The method creates light, durable, and compact doses that would be ideal for shipping Ebola vaccine, for example, to affected regions of Africa, the researchers say. The process adds only marginal cost to preparing a vaccine and eliminates almost all the cost of transporting it – which can account for 80 per cent of the total cost of inoculation.
Combining the vaccines and the sugars – pullulan and trehalose – is almost as simple as stirring cream and sugar into coffee, the researchers say. The storage technology was created by chemical engineers at McMaster, who had already demonstrated its effectiveness in other applications, such as an edible coating that can prolong the shelf life of fruits and vegetables.
To apply the technology to vaccines, the engineers collaborated with health sciences colleagues across campus who specialize in virology and immunology. Their work is published today in the journal Scientific Reports and also appeared on the front page of the Globe and Mail newspaper.
“This, to us, is the ultimate application of this technology,” said the paper’s lead author Vincent Leung, an assistant professor of Chemical Engineering. “To imagine that something we worked on in the lab could one day be used to save people’s lives is very exciting.”
The invention is significant because it can replace the cumbersome “cold chain” – constant storage at temperatures between 2C and 8C – which is currently necessary to keep anti-viral vaccines viable. Maintaining the cold chain is a significant barrier to inoculating people in remote or poor regions of the world, where the infrastructure to refrigerate and transport vaccines smoothly may not be available.
“You can spend all kinds of money developing a vaccine, but if it is deactivated by high temperature an hour before you can give it to someone, it doesn’t matter,” says co-author Ali Ashkar, a professor of Pathology and Molecular Medicine specializing in immunology.
The cold-chain challenge is so great, the researchers say, that in some regions, vaccines must be transported by camels bearing solar-powered mini-refrigerators. There are some populations that never receive vaccines.
“If you can’t get vaccines to the places where people need them, there’s no point in having them,” says co-author Matthew Miller, an assistant professor in the Department of Biochemistry and Biomedical Sciences whose laboratory specializes viral pathogens.
Not being able to get vaccines to isolated areas makes it impossible to eradicate deadly viruses. Unchecked, such viruses can devastate local populations and reach exposed pockets in more populated countries where religious, cultural or other concerns have diminished the proportion of vaccinated individuals. Such a scenario has recently been playing out in in a measles outbreak in the US northwest and Vancouver, BC.
The new vaccine-storage method suspends the active components of a vaccine in a tiny one-dose container filled with a sugar-gel combination that dries to seal in the vaccine. Later, clinicians reconstitute the vaccine with water and administer it to patients as they ordinarily would.
“Often, complex problems have simple solutions. It just takes the right team,” says Miller. “The best research comes from merging fields, when you do something with someone else that you couldn’t do alone.”
The researchers have proven the method to be viable using two sample vaccines – influenza virus and herpes simplex virus – to inoculate and test mice by exposing them to the viruses because the immune response of mice is similar to that of humans. The materials in the storage medium are already approved by the US Food and Drug Administration, simplifying the path to commercialization.
“All the pieces are ready to go,” says co-author Carlos Filipe, chair of Chemical Engineering at McMaster. “It’s actually quite simple compared to the technology required to create a vaccine itself.”
The researchers are working with a commercial partner to get the technology to market.
The Latest on: Vaccine storage
via Google News
The Latest on: Vaccine storage
- Cyprus signs up for new vaccine against Covid-19on August 2, 2022 at 5:42 am
Cyprus is one of 14 EU member states to sign up to a joint procurement contract with Spanish pharmaceutical firm Hipra for its protein vaccine against Covid-19. The agreement was signed on Tuesday ...
- After vaccine delays, Monkeypox is spreading—and at risk of becoming endemic, doctors warnon July 29, 2022 at 7:00 am
The virus has spread to more than 4,900 Americans, including two children, after critical delays in distributing vaccines.
- Moderna COVID vaccine is more effective in older and sicker veterans over timeon July 28, 2022 at 8:44 pm
Researchers report the higher effectiveness of the Moderna COVID-19 vaccine as compared to the Pfizer COVID-19 vaccine.
- More than 780K doses of monkeypox vaccine available Friday; San Francisco declares state of emergencyon July 28, 2022 at 6:09 pm
The government distributed 300,000 doses this month and announced Wednesday another 786,000 are available – bringing the total to over 1.1 million.
- We Don't Need a White House Monkeypox 'Coordinator.' We Just Need the Vaccines.on July 27, 2022 at 3:35 pm
As monkeypox spreads in the U.S. and people scream for vaccines, the Biden administration instead mulls unneeded coordination efforts ...
- Global Vaccines Storage Equipment Market 2022 Top Key Players, Industry Demand, Future Estimations and Key Tactics to 2028on July 27, 2022 at 12:56 pm
Added to the extensive database of MarketsandResearch.biz titled Global Vaccines Storage Equipment Market 2022 ...
- NJ designates Camden County a regional storage hub for monkeypox vaccineon July 27, 2022 at 5:02 am
Camden County is serving as one of six storage hubs in New Jersey for the monkeypox vaccine. Due to the small distribution of the vaccine nationwide, the Camden County regional hub only has 50 doses ...
- The future of COVID vaccines could be sprays, not shotson July 26, 2022 at 4:14 pm
Experts gathered at a White House COVID vaccine summit on Tuesday to discuss improving inoculation and developing new options for the future ...
- DMS says four decades old smallpox vaccine in storage still effective against monkeypoxon July 25, 2022 at 1:21 am
BANGKOK: Despite there being no dedicated vaccine for monkeypox currently available, health authorities in Thailand have said that smallpox vaccines that are decades old may be used instead.
- Is This Vaccine Stock a Buy After Big News?on July 22, 2022 at 3:45 am
But can FDA approval be enough to carry the stock upward? On July 13 the FDA granted an Emergency Use Authorization (EUA) for the Novavax COVID-19 vaccine, CovoVax, following European Medicines Agency ...
via Bing News